Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 16:2019:7284691.
doi: 10.1155/2019/7284691. eCollection 2019.

Association between MIC-1 and Type 2 Diabetes: A Combined Analysis

Jianan Lu  1 , Yue Zhang  1 , Xingxuan Dong  1 , Jiawen Lu  1 , Chen Zhang  1 , Jieyu Liu  1 , Qingzhou Yu  1 , Haoyue Teng  1 , Qingkui Yao  2 , Jieyun Yin  1 , Liqiang Qin  3
Affiliations
Review

Association between MIC-1 and Type 2 Diabetes: A Combined Analysis

Jianan Lu et al. Dis Markers. .

Abstract

Background and objectives: Type 2 diabetes mellitus (T2DM) is an epidemic disease that endangers human health seriously. Recently, a large number of reports have revealed that macrophage-inhibiting cytokine-1 (MIC-1) is linked with T2DM, but the results were inconclusive. The aim of this study was to perform bioinformatics analysis of the association between MIC-1 and T2DM.

Material and methods: Datasets and relevant literatures were searched in Gene Expression Omnibus (GEO), PubMed, Google Scholar, and Web of Science till September 20, 2019. Expression levels of MIC-1 were extracted, pooled, and compared between T2DM cases and controls.

Results: In summary, 11 GEO datasets and 3 articles with 421 T2DM cases and 711 controls were finally included. The expression level of MIC-1 was significantly higher in T2DM patients compared with controls, with a standard mean difference (SMD) of 0.54 and a 95% confidence interval (95% CI) of 0.24-0.83; in blood samples, the difference was still significant (SMD = 0.65; 95%CI = 0.24-1.06). Meanwhile, the expression level of MIC-1 plays a significant role in differentiating T2DM cases from controls; the combined sensitivity, specificity, and odds ratio were 0.83 (95%CI = 0.72-0.90), 0.59 (95%CI = 0.45-0.72), and 1.64 (95%CI = 1.35-1.99), respectively. The summary receiver operating characteristic (SROC) curve demonstrated that the area under the curve (AUC) was 0.81 (95%CI = 0.77-0.84).

Conclusion: Our results suggested that the expression levels of MIC-1 were significantly higher in T2DM patients in multiple tissues including blood samples.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1
Figure 1
Search flow diagram for literature selection.
Figure 2
Figure 2
Forest plot showing SMD of MIC-1 expression between T2DM patients and nondiabetes people. The random effect model was used in all groups.
Figure 3
Figure 3
Forest plot showing SMD of MIC-1 expression in blood samples between T2DM patients and nondiabetes people. The random effect model was used in all groups.
Figure 4
Figure 4
Diagnostic analysis of MIC-1 value in T2DM patients.
Figure 5
Figure 5
Summary receiver operating characteristic curve of MIC-1 value in T2DM patients.
Figure 6
Figure 6
Sensitivity analysis of the value of MIC-1 in T2DM patients.
See this image and copyright information in PMC

References

    1. Cho N. H., Shaw J. E., Karuranga S., et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023. - DOI - PubMed
    1. Ogurtsova K., da Rocha Fernandes J. D., Huang Y., et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024. - DOI - PubMed
    1. Bruno G., Runzo C., Cavallo-Perin P., et al. Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin, Italy. Diabetes Care. 2005;28(11):2613–2619. doi: 10.2337/diacare.28.11.2613. - DOI - PubMed
    1. Franz M. J., Boucher J. L., Rutten-Ramos S., VanWormer J. J. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Journal of the Academy of Nutrition and Dietetics. 2015;115(9):1447–1463. doi: 10.1016/j.jand.2015.02.031. - DOI - PubMed
    1. Chatterjee S., Khunti K., Davies M. J. Achieving glycaemic control with concentrated insulin in patients with type 2 diabetes. Drugs. 2019;79(2):173–186. doi: 10.1007/s40265-018-1048-6. - DOI - PubMed

MeSH terms

Substances